TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: serum level of alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rifapentine exposure level 24 hours after drug ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearing peripheral malaria parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Radiographic Bone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual mammography adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Survival without lung transplant
Endpoint domain: Mortality/survival
Primary endpoint: CIN remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time required for left atrial access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ctDNA detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volume of the large zygomatic muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active and passive range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of mitiglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of mitiglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation trend of circulating tumor cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Low-density Lipoprotein (LDL) Cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nephrotoxicity related to CYP3A5 genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Experienced Asthma Exacerbation(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Level of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of xenon in blood sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Successful Contact Lens Wearers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in the appearance of post-surgical scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SBA GMT at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurocognitive Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of sepsis vs. non-sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to withdrawal from study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of DSA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volunteers' Perception of Needle Penetration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Crestal Bone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Bone Mineral Density at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Vitamin D levels at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Alkaline Phosphatase at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t Plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment interruption due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of MRDTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Children Who Developed Autism
Endpoint domain: Mortality/survival
Primary endpoint: Verbal Numeric Rating Scale (VNRS) less than or equal to 2 out of 10 during contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Insulin metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Global Impression-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aberrant Behavior Checklist- Irritability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breast volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin E change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of ICP values obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of PLX73086, as measured by adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Central Macular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VOC Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of buprenorphine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Short term change in cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long term change in cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of solicited local and general adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Serum plaque reduction neutralization titer 50% (PRNT50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Biopsy-proven Cancers (Gleason 6+) Missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Biopsy-proven Cancers (Gleason 7+) Missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of Intramuscular lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of mitochondrial activity in PAH skeletal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Susceptibility of coronary artery aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious pressure ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Exhaled CO Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCtau of Velpatasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of GS-331007
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Discontinued Study Drug Due to TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent Clinical Symptoms of Incompetent Small Saphenous Vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Ocular pharmacokinetic in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI erosion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of anecortave acetate in rubeosis iridis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of FGF19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neuronal activity in CNS reward and satiety circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain and disability using SPADI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Antibody Concentrations for Pertussis Toxoid, Filamentous Hemagglutinin and Pertactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Premenstrual symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CLABSI
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of chlamydia DNA in tubal and ovarian tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative gastrointestinal system disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of abdominal fat layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased patient confidence about Survivorship Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ultrasound liver shear wave speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Child HCAHPS Response Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Meeting Dutch PA guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tooth vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of patients receiving clinical assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of gestational diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression to referable diabetic retinopathy/maculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Increase in endsystolic elastance of the right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self-esteem from baseline to 20-weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Global Happiness from baseline to 20-weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sense of Belonging at School from baseline to 20-weeks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean Inpatient Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in patient self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dynamic blood glucose changes (average blood glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance index changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume injected at time of outflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold of bacterial tolerance yielding positive healing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of disease recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Plasma Concentration for Alisertib (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoactive effect of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sympathetic activity (noradrenaline spillover, spectral analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hsCRP Serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Bisphenol A concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants administered omecamtiv mecarbil
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of Ratio of breathing sectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coronary sinus lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients achieving very good partial response (VGPR) + complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient survival associated with relapse rate after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Patient survival associated with relapse rate after chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Percentage overlap of identified areas of necrosis determined by ICG and clinical standard of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve the peak fluorescent signal from necrotic tissue using ICG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with ANC < 1.0 × 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful clubfoot correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects without vomiting, retching, or nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of plantar keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Grading of dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to depressive relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of depression free days at 12 month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sought Second Prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma concentration of napabucasin and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary concentration of napabucasin and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal concentration of napabucasin and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Sessions Completed
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Serum cystatin-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine β_2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Participants reaching one year post-op
Endpoint domain: Mortality/survival
Primary endpoint: Validity of patient self reporting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comfort in reporting intimidation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of intimidation after intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence and frequencies of migraines and other types of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in response on the Self-Referent Encoding Task (SRET)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in colon transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in subjective appetite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of microparticules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Epidermal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surface Roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Attenuation Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of women who will not feel pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of intraoperative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in care dependency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Anterior Chamber Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Absence of Ocular Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percent change in apparent diffusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Masked hypertension prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression Free Survival Time
Endpoint domain: Mortality/survival